Alvotech announces topline results from a confirmatory clinical study for avt05, a proposed biosimilar for simponi® (golimumab)

Reykjavik, iceland, april 24, 2024 (globe newswire) -- alvotech (nasdaq: alvo), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today positive topline results from a confirmatory clinical study for avt05, alvotech's proposed biosimilar to simponi® and simponi aria® (golimumab). alvotech is the first company to announce positive topline results of a clinical trial using a proposed biosimilar to simponi and simponi aria and is one of only two companies known to have initiated such a patient study.
ALVO Ratings Summary
ALVO Quant Ranking